Navigation Links
TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
Date:5/1/2009

LA JOLLA, Calif., May 1 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported financial results for the first quarter ended March 31, 2009. For the three-month period, the company posted a net loss of $2.1 million. Cash and cash equivalents totaled $6.3 million at March 31, 2009.

On April 15, 2009, the Company hired Merriman Curhan Ford as its financial advisor to assist in the evaluation of strategic options, including the possible sale of the Company or its assets.

Financial Results

Revenue for the three month period ended March 31, 2009 was $0 compared to revenue of $2.0 million for the same period in 2008. Operating expenses for the quarter ended March 31, 2009 were $2.1 million, with $0.9 million attributable to research and development. This compares to operating expenses of $6.7 million and research and development expenses of $5.3 million for the same period last year. The company reported a net loss for the quarter ended March 31, 2009 of $2.1 million compared to a net loss of $3.9 million for the previous year.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, acute and chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press rel
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Sterlitech is proud to announce ... its stable of products . These additional ... and include membrane filters with surface charges. ... demand for our membrane process testing equipment, and correspondingly, ... sheet membranes,” explains Sterlitech President Mark Spatz. “The ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... 28, 2014 PrimeSource Building Products, ... selected SoundConnect to support their communication ... audio and web conferencing platform GlobalMeet powered by ... employees’ needs. SoundConnect delivers award winning “results ... Building Products will be utilizing GlobalMeet powered ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3
... , , , , , ... , , Co-transfections , ... DNA constructs work in your cell line. Also, determine the ratio of DNA ,to FuGENE ... ,provides good expression levels. Then, perform the transfection, ensuring the ,DNA / FuGENE 6 Reagent ...
... , , , , , , ... , , General , Keep an eye ... for optimal cell density from the beginning to, the end of transfection. , ... Cells , Dividing cells tend to be more accessible for uptake and expression of, ...
... , , , , ... can encompass all aspects of genome projects from shotgun ... Our personal project managers , consult with clients to ... project goals and are available to manage the project from start to finish. , ...
Cached Biology Technology:Uses and Applications of FuGENE 6 Transfection Reagent 2General Considerations for Successful Transfection Experiments 2WHOLE GENOME SEQUENCING 2WHOLE GENOME SEQUENCING 3
(Date:8/28/2014)... of the world,s most important crop-producing countries will be ... century if current trends continue, according to a new ... than one-in-ten pest types can already be found in ... If this spread advances at its current rate, scientists ... will be overwhelmed by pests within the next 30 ...
(Date:8/27/2014)... mastodons, short-faced bears, giant ground sloths, saber-toothed cats and ... years ago at the end of the Pleistocene period. ... debated by scientists who, until recently, could only speculate ... UC Santa Barbara,s James Kennett, professor emeritus in the ... with Earth played a major role in the extinction. ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html ... to assess individuals on the basis of their ... and identification of both physiological traits such as ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2Nanodiamonds are forever 2Nanodiamonds are forever 3Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... Academy of Sciences will host the Fifth Annual ... design of oligosaccharides and proteins for materials and ... on the following areas: (1) synthetic and biosynthetic ... these macromolecules in materials science and glycobiology, (2) ...
... Kidney stones strike an estimated 1 million Americans each year, ... is among the worst known to man (or woman). ... Medicine in St. Louis provides evidence to explain why some ... Their discovery opens the door to finding effective drug treatments ...
... Concordia University is bringing us one step closer to clean ... a battery-like enzyme can store energy from seconds to hours, ... Chemical Society shows. Concordia Associate Professor Lszl Klmn ... graduate students Sasmit Deshmukh and Kai Tang has been ...
Cached Biology News:Kidney stone mystery solved 2Kidney stone mystery solved 3Nature's billion-year-old battery key to storing energy 2
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... is used to detect the appearance of ... infected cells as early as 8-24 hours ... FastPlax Titer Kit, which allows determination of ... The FastPlax Antibody can also be ...
Biology Products: